Page 4 - இயக்குதல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இயக்குதல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இயக்குதல் Today - Breaking & Trending Today

Director leaves his comfort zone for confronting drama


Director leaves his comfort zone for confronting drama
26 Jan, 2021 02:51 AM
3 minutes to read
In rehearsal for Blind Eye are Chris McKenzie (left), Annie Whitfield, Joan Street and Mike Street. Photo / Jacqui McKenzie
In rehearsal for Blind Eye are Chris McKenzie (left), Annie Whitfield, Joan Street and Mike Street. Photo / Jacqui McKenzie
Chris McKenzie is directing Amdram s latest production, Blind Eye, a play by April Phillips.
With a cast comprising Chris, as well as Annie Whitfield and Joan and Mike Street, there was no shortage of directorial choice when original director Talia Annear had to withdraw.
Talia had already done a lot of the blocking, says Chris. Although he stepped up as director, he says it has been a real team effort. ....

April Phillips , Fannie Whitfield , Wally Matthews , Dick Whittington , Chris Mckenzie , Talia Annear , Blind Eye , Mike Street , Amdram Theatre , ஏப்ரல் பிலிப்ஸ் , அன்னயே வைட்ஃபீல்ட் , வாலி மேத்யூஸ் , டிக் வைட்டிங்டன் , கிறிஸ் மகெந்ஸீ , தாலியா ஆண்டு , குருட்டு கண் , மைக் தெரு ,

Lilly, Merus Collaborate To Discover T-Cell Re-Directing Bispecific Antibodies


Lilly, Merus Collaborate To Discover T-Cell Re-Directing Bispecific Antibodies
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY), and Merus N.V. (MRUS) have collaborated to discover novel T-cell re-directing bispecific antibodies. As per the collaboration, Merus is eligible to receive for a total of up to about $1.6 billion, Lilly said in a statement.
Loxo Oncology at Lilly, a research and development group of Eli Lilly and co., and Merus have reached a research collaboration and license agreement that will leverage Merus proprietary Biclonics platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. ....

Eli Lilly , Loxo Oncology , எலி லில்லி ,